An investigation on behalf of investors, who currently hold shares of Bioverativ Inc (NASDAQ:BIVV), was announced concerning whether the takeover of Bioverativ Inc. by Sanofi is unfair to NASDAQ:BIVV stockholders.

The investigation by a law firm concerns whether certain officers and directors of Bioverativ Inc breached their fiduciary duties owed to NASDAQ:BIVV investors in connection with the proposed acquisition.

Waltham, MA based Bioverativ Inc. (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. On January 22, 2018, Sanofi and Bioverativ Inc., have entered into an agreement under which Sanofi will acquire all of the outstanding shares of Bioverativ for $105 per share in cash, representing an equity value of approximately $11.6 billion.

However, the investigation concerns whether the offer is unfair to NASDAQ:BIVV stockholders. More specifically, the investigation concerns whether the Bioverativ Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

Bioverativ Inc reported that its annual Total Revenue rose from $560.30 million in 2015 to $887.40 million in 2016 and that its Net Income increased from $108.60 million in 2015 to $439.60 million in 2016.